New vaccine trial aims to shield vulnerable children from pneumonia

NCT ID NCT07252791

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the safety and immune response of the 20-valent pneumococcal vaccine (PCV20) in children, adolescents, and young adults aged 2-25 with autoimmune rheumatic diseases like juvenile arthritis. All 114 participants will receive one dose of PCV20, and researchers will measure antibody levels and side effects for up to 6 months. The goal is to see if this vaccine can better protect this vulnerable group from pneumococcal infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 20-valent pneumococcal conjugate vaccine (PCV20)
What this could lead to: If successful, this could show that PCV20 is safe and effective in protecting children with autoimmune rheumatic diseases from serious pneumococcal infections.
What could go wrong: This is a Phase 4 study with a relatively small group (114 participants). Results may not apply to all patients, and the vaccine may not produce a strong immune response in those on immunosuppressive therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE RHEUMATOLOGIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease juvenile dermatomyositis juvenile idiopathic arthritis pediatric systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE RHEUMATOLOGIC DISEASE

Contacts and locations

Locations

Hospital das Clinics da Faculdade de Medicina da Universidade de Sao Paulo
RECRUITING

São Paulo, São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.